Scisparc Using Psychedelics to Target Weight Loss

Scisparc Ltd. (Nasdaq: SPRC) has achieved positive results in a preclinical trial observing the safety and impact of a combination treatment on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior.

The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide™, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression. The trial was conducted as part of a collaboration between SciSparc and Clearmind Medicine (Nasdaq: CMND).

Oz Adler, SciSparc’s Chief Executive Officer, said, “I am encouraged by the positive results from our recent preclinical trial, which represents another milestone in our ongoing efforts to develop safe and effective innovative therapies. The successful collaboration between SciSparc and Clearmind continues to demonstrate the potential of our Combination Treatment to address obesity and related health challenges. The trial’s findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment’s efficacy and safety.”


In November, Scisparc initiated a clinical trial using its proprietary therapy, SCI-210, a combination of cannabidiol (CBD) and PEA, targeting Autism Spectrum Disorder (ASD) symptoms in children. The trial will enroll 60 participants between the ages of 5-18 years old and will measure how SCI-210 compares to standard CBD treatment in managing ASD symptoms.

This month, the company also announced that MitoCareX Bio Ltd., its joint venture company focused on the discovery and development of drugs for cancer treatment, has achieved positive results with the development of its laboratory capabilities by establishing a variety of small-molecule screening platforms.

As per the Agreement, reaching the second milestone results triggers the condition that SciSparc invest an additional $600,000 into the joint venture within 30 days of the date the second milestone was achieved. Following this investment, the Company will hold 50.1% of the issued and outstanding share capital of MitoCare X Bio.

About SciSparc Ltd.

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.

Share This Article


About the Author

Scisparc Using Psychedelics to Target Weight Loss

Catie Corcoran

Biotech Editor